

QIBA Dynamic Contrast-Enhanced (DCE) MRI Biomarker Committee (BC) Meeting

Monday, June 13, 2022, at 11 a.m. (CT)

Meeting Summary

In attendance

Caroline Chung, MD (Co-chair)

James O'Connor, MBBS, PhD (Co-chair)

Nima Ameli, MD

Ararat Chakhoyan, PhD

Lucas McCullum, MS

Sina Nazemi, MD

Nancy Obuchowski, PhD

Mark Shiroishi, MD

RSNA staff

Susan Stanfa

Topics Discussed:

- DCE-MRI BC leadership update
 - Dr. James O'Connor accepted the invitation to serve as DCE-MRI BC Co-chair, effective on June 1, 2022
 - Professor of Radiology in the Division of Cancer Sciences at The University of Manchester and an Honorary Consultant Radiologist at The Christie Hospital in Manchester
 - Holds a Cancer Research UK Advanced Clinician Scientist Fellowship, where he develops MRI biomarkers of cancer to evaluate response and relapse for drug-radiotherapy combinations
 - Co-leads the Cancer Research UK National Cancer Imaging Translational Accelerator (NCITA) network
 - Dr. Chung to transition out of her DCE-MRI BC Co-chair role to focus on her QIBA Vice Chair role, however, she plans to attend DCE-MRI BC meetings as often as her schedule allows
- BC members introduced themselves, providing information on current and past roles, and research areas of interest
- Current status of the DCE-MRI BC, future applications, and getting biomarkers into practice
- Dearth of repeatability data in the literature and challenges initiating test-retest studies
- Dr. O'Connor's research studies and test-retest data that were acquired
- Progress on BC internal review of public comments, corresponding DCE Profile edits, and next steps

Action Items / Next Steps:

- DCE-MRI was widely used in drug company clinical trials in the mid-2000s and obtaining funding for test-retest studies using DCE-MRI was not as challenging then as it is today
- Logistical and ethical concerns regarding subject follow-up scanning on different days with repeat IV placement, the need for repeat GBCA administration and theoretical concerns related to gadolinium deposition to be addressed
- [Public Comment Resolutions](#) continue to be incorporated into the [DCE-MRI BC Profile](#)
 - Dr. Shiroishi to finish incorporating remaining clinical comments into Profile
 - Once the Profile is completed, internal BC review will proceed
 - Lastly, a BC vote-to-publish the Profile as stage 2 Consensus will be followed by an MR CC vote
- Bi-weekly DCE-MRI BC meetings to continue, but a TF may be formed to focus on repeatability work

Next meeting: Monday, June 27, 2022, at 11 a.m. (CT) [2nd & 4th Mondays of each month]

Zoom meeting link: <https://rsna-org.zoom.us/j/86058676145?pwd=TjYySW8vb0hhUXE4TEZHVkfSOHN5QT09>

Meeting ID: 860 5867 6145

Passcode: DCE

RSNA Staff attempt to capture the names of committee members participating on Zoom meetings. However, **if attendees join only by phone or do not use recognizable named, identification is not possible.** Participants are welcome to contact RSNA staff at QIBA@RSNA.org if their attendance is not reflected in meeting summaries.